Stock Analysis
General
Library
Could $500 a month in RYTM grow toward $117K? 
Its incredible five-year climb comes with real risks and sharp swings.
Hit play to uncover the numbers and what consistent investing could potentially build!
Imagine setting aside $500 a month for $RYTM for five years, buying a fixed dollar amount on a schedule, a method called dollar-cost averaging. In our example, the buy happens on the first trading day on or after the 26th of each month, from Oct 26, 2021 through Sep 28, 2026: 60 buys, $30,000 in total.
5-Year Growth & Value: RYTM closed at $11.10 on Oct 26, 2021 and at $89.27 on Oct 23, 2026, a price gain of about 704.2% (about 8x), or roughly 51.8% a year compounded (the steady yearly rate that would give the same total gain).
Investment Returns: In that example, the $30,000 invested through dollar-cost averaging would have been worth about $117,380 at the Oct 23, 2026 close (about 3.9 times the money put in), while a single $10,000 lump sum invested on Oct 26, 2021 would have become about $80,420. (Price only: no dividends, fees or taxes. These are examples, not forecasts.)
High & Low Extremes: The highest close of the past 52 weeks was $117.62 on Dec 11, 2025 (intraday high $122.20 that day), so the Oct 23, 2026 close sat about 24.1% below it. The 52-week low was $75.82 (closing low, Mar 27, 2026). The lowest close of the five years was $3.12 on May 19, 2022, about 71.9% below the $11.10 start.
Perspective on Chart: The chart shows +704.23%, the same five-year, price-only gain (about +704.2%) measured to a single close (Oct 23, 2026). A few days of trading can move it by tens of percentage points.
Get daily 5-year horizon stock picks in your inbox. Long-term investing wins, and our featured stocks have already beaten the S&P 500. Subscribe now!
Caution: past pace rarely continues. Rhythm is a commercial-stage rare-disease biotech that is not yet consistently profitable, and its Q3 2026 results are due Tuesday, Nov 3, 2026 at 8:00 a.m. ET. The stock has also fallen from its $117.62 closing high on Dec 11, 2025, a reminder that prices can drop sharply even while sales of IMCIVREE grow. The same lesson as the five stocks below applies: a strong five-year chart is a reason to research, not proof of what comes next.
